Asset / Drug

M&A / Partnership

Drug and asset intelligence for M&A / Partnership with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 0
Catalysts: 5
Stage: Development stage unavailable

Sponsor company

Pfizer →

Recent signals

No signals indexed for this entity yet.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(5)

Topline Data

Merck — M&A / Partnership

Monitor the completion of the tender offer and any subsequent integration announcements from Merck.

June 17, 2026 · N/A

Topline Data

Roche — M&A / Partnership

Monitor the initiation of Phase 3 trials for bexobrutideg in summer 2026 and any updates on clinical efficacy and safety data.

June 16, 2026 · N/A

Topline Data

Roche — M&A / Partnership

Monitor the initiation of Phase 3 trials for bexobrutideg and any updates on clinical efficacy and safety data.

June 16, 2026 · N/A

Topline Data

Roche — M&A / Partnership

Monitor the closing of the transaction, expected in the second half of the year, and subsequent integration of PathAI's technology into Roche's offerings.

June 16, 2026 · N/A

Topline Data

Pfizer — M&A / Partnership

Monitor the progress of the co-development programs and any regulatory approvals that may arise from this collaboration.

June 16, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Hematology · BTK Degrader →

Oncology · ADC →

Oncology · B-cell Malignancies →

Oncology · Digital Pathology →

Oncology · Small Molecule →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.